

Press release for immediate release

## **Genomtec strengthens the management board - Charudutt Shah joins the company**

*Wrocław, Poland - May 31, 2021* - Genomtec SA, a company listed on the NewConnect market dealing with the development of innovative medical technologies used in genetic diagnostics in the place of patient care - POCT announced that Charudutt Shah is joining the board. The newly appointed member of the Genomtec board is a senior executive with many years of international experience, incl. in the area of business development, marketing and sales management and strategic planning in the clinical genetic diagnosis sector. He will start work at Genomtec on August 1, 2021.

*- We are strengthening our existing competences in the field of international business relations and the development of commercial operations in the organization. Charudutt Shah brings a deep understanding of the challenges and opportunities inherent in commercializing novel molecular diagnostics, and a track record of getting the best market success for a company and its people. His experience will help us in the commercialization of the mobile diagnostic system - Genomtec ID, as well as in other projects. Welcome on board - said Miron Tokarski, co-founder and president of Genomtec.*



Charudutt Shah has several years of leadership experience in the area of product commercialization, brand development and partnership with international entities. Currently, he holds the position of Marketing Director of BioMérieux SA based in Lyon, France - the world leader in laboratory diagnostics and research on infectious diseases, where he is responsible for commercial marketing in Europe, Middle East and Africa (EMEA). In his role, he oversees the launch and marketing of BioFire's syndromic infectious disease panels and instruments that rapidly identify pathogens. A major focus of his efforts are in developing go to market strategies, driving clinician awareness, market access and bringing innovative testing solutions to various healthcare ecosystems to improve patient care.

Previously, he was associated with Spartan Bioscience, based in Ottawa, Ontario, where, as Business Development Director he was responsible for sales, marketing and product distribution strategies internationally. In the years 2010 - 2014 he was a Global Marketing Manager at Luminex Corporation based in Toronto, Ontario where he managed the industry's first multiplex PCR Respiratory Viral panel including a portfolio of other infectious disease panels.

He has spent over a decade in commercial roles within the Diagnostic Industry developing marketing strategies, creating distribution partnerships, addressing unmet customer needs, leading product innovation and introducing new products to the market.

*- I am extremely proud that I will be able to participate at this important stage in the development of Genomtec and its flagship solution, Genomtec ID. The company is an unusual startup - known and closely watched by global giants, and the innovation of its technology has been appreciated in numerous international competitions. I am excited to join Miron Tokarski and his talented team as they unleash their platform to create a new class of breakthrough point of care diagnostics. I believe that my experience, skills and ability to work closely with the business and scientific community around the world will be helpful in the further development of Genomtec and its innovative products that can change the world - said Charudutt Shah, a newly appointed member of the Genomtec board.*

Charudutt is a graduate of the University of Toronto and holds both a Bachelors of Applied Science and Engineering degree as well as a Masters of Biotechnology and Management degree. He also holds a certificate of Alliance Management from the Canadian Healthcare Licensing Association.

Genomtec's flagship solution – the Genomtec ID is a mobile diagnostic system employing microfluidic system and the proprietary, patented SNAAT® technology. This innovative diagnostic system will be able to carry out several tests from one sample simultaneously, including causal determination of respiratory tract infections or sexually transmitted diseases, even in 15 minutes. Genomtec ID will be used for point of care diagnostics, i.e., in doctor's offices, emergency department, and even a pharmacy.

####

**Additional information available at:**

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

m.kicinska@genomtec.com

**About Genomtec S.A.**

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.



The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. The seat of Genomtec SA is located in Wroclaw in Poland and Ashford in United Kingdom.

More information: [www.genomtec.com](http://www.genomtec.com)